Publikationen der ALS-Forschungsgruppe an der Charité
Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach
Funke A, Spittel S, Grehl T, Grosskreutz J, Kettemann D, Petri S,
Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation
Kettemann D, Funke A, Maier A, Rosseau S, Meyer R, Spittel S,
Interleukin-1 Antagonist Anakinra in Amyotriphic Lateral Sclerosis – A Pilot Study
Maier A, Deigendesch N, Müller K, Weishaupt JH, Krannich A, Röhle R,
Provision of assistive devices in amyotrophic lateral sclerosis. Analysis of 3 years case management in an internet-based supply network
Funke A, Grehl T, Großkreutz J, Münch C, Walter B, Kettemann D,
Severe loss of appetite in amyotrophic lateral sclerosis patients: online self-assessment study
Holm T, Maier A, Wicks P, Lang D, Linke P, Münch C,
Concomitant amyotrophic lateral sclerosis and paraclinical laboratory features of multiple sclerosis: coincidence or causal relationship?
Borisow N, Meyer T, Paul F. Concomitant amyotrophic lateral sclerosis and paraclinical
Publikationen mit Beteiligung der ALS-Forschungsgruppe an der Charité
Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis
Fernández-Santiago R, Hoenig S, Lichtner P,
Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop
Ludolph AC, Bendotti C, Blaugrund E,
Familial ALS in Germany: origin of the R115G SOD1 mutation by a founder effect
Niemann S, Joos H, Meyer T,
The role of excitotoxicity in ALS – what is the evidence?
Ludolph AC, Meyer T, Riepe MW.J
Antiglutamate therapy of ALS – which is the next step?
Ludolph AC, Meyer T, Riepe MW.J
Molecular biology findings in amyotrophic lateral sclerosis
Bachus R, Claus A, Meyer T,
